Jamie S Ostroff1, Amy Copeland2, Sarah P Borderud3, Yuelin Li3, Donna R Shelley4, Claudia I Henschke5. 1. Memorial Sloan Kettering Cancer Center, New York, NY; ostroffj@mskcc.org. 2. Lung Cancer Alliance, Washington, DC; 3. Memorial Sloan Kettering Cancer Center, New York, NY; 4. New York University, New York, NY; 5. Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
INTRODUCTION: Lung cancer screening represents an opportunity to deliver smoking cessation advice and assistance to current smokers. However, the current tobacco treatment practices of lung cancer screening sites are unknown. The purpose of this study was to describe organizational priority, current practice patterns, and barriers for delivery of evidence-based tobacco use treatment across lung cancer screening sites within the United States. METHODS: Guided by prior work examining readiness of health care providers to deliver tobacco use treatment, we administered a brief online survey to a purposive national sample of site coordinators from 93 lung cancer screening sites. RESULTS: Organizational priority for promoting smoking cessation among lung cancer screening enrollees was high. Most sites reported that, at the initial visit, patients are routinely asked about their current smoking status (98.9%) and current smokers are advised to quit (91.4%). Fewer (57%) sites provide cessation counseling or refer smokers to a quitline (60.2%) and even fewer (36.6%) routinely recommend cessation medications. During follow-up screening visits, respondents reported less attention to smoking cessation advice and treatment. Lack of patient motivation and resistance to cessation advice and treatment, lack of staff training, and lack of reimbursement were the most frequently cited barriers for delivering smoking cessation treatment. CONCLUSIONS: Although encouraging that lung cancer screening sites endorsed the importance of smoking cessation interventions, greater attention to identifying and addressing barriers for tobacco treatment delivery is needed in order to maximize the potential benefit of integrating smoking cessation into lung cancer screening protocols. IMPLICATIONS: This study is the first to describe practice patterns, organizational priority, and barriers for delivery of smoking cessation treatment in a national sample of lung cancer screening sites.
INTRODUCTION:Lung cancer screening represents an opportunity to deliver smoking cessation advice and assistance to current smokers. However, the current tobacco treatment practices of lung cancer screening sites are unknown. The purpose of this study was to describe organizational priority, current practice patterns, and barriers for delivery of evidence-based tobacco use treatment across lung cancer screening sites within the United States. METHODS: Guided by prior work examining readiness of health care providers to deliver tobacco use treatment, we administered a brief online survey to a purposive national sample of site coordinators from 93 lung cancer screening sites. RESULTS: Organizational priority for promoting smoking cessation among lung cancer screening enrollees was high. Most sites reported that, at the initial visit, patients are routinely asked about their current smoking status (98.9%) and current smokers are advised to quit (91.4%). Fewer (57%) sites provide cessation counseling or refer smokers to a quitline (60.2%) and even fewer (36.6%) routinely recommend cessation medications. During follow-up screening visits, respondents reported less attention to smoking cessation advice and treatment. Lack of patient motivation and resistance to cessation advice and treatment, lack of staff training, and lack of reimbursement were the most frequently cited barriers for delivering smoking cessation treatment. CONCLUSIONS: Although encouraging that lung cancer screening sites endorsed the importance of smoking cessation interventions, greater attention to identifying and addressing barriers for tobacco treatment delivery is needed in order to maximize the potential benefit of integrating smoking cessation into lung cancer screening protocols. IMPLICATIONS: This study is the first to describe practice patterns, organizational priority, and barriers for delivery of smoking cessation treatment in a national sample of lung cancer screening sites.
Authors: Elyse R Park; Ilana F Gareen; Sandra Japuntich; Inga Lennes; Kelly Hyland; Sarah DeMello; JoRean D Sicks; Nancy A Rigotti Journal: JAMA Intern Med Date: 2015-09 Impact factor: 21.873
Authors: Amy K Ferketich; Gregory A Otterson; Mark King; Nathan Hall; Kristine K Browning; Mary Ellen Wewers Journal: Lung Cancer Date: 2011-11-15 Impact factor: 5.705
Authors: Sarah Price; Brian Hitsman; Anna Veluz-Wilkins; Sonja Blazekovic; Tarah R Brubaker; Frank Leone; Anita Hole; E Paul Wileyto; Corey Langer; Ravi Kalhan; Jyoti Patel; Robert Schnoll Journal: Psychooncology Date: 2016-05-24 Impact factor: 3.894
Authors: Jordan M Neil; Caylin Marotta; Irina Gonzalez; Yuchiao Chang; Douglas E Levy; Amy Wint; Kimberly Harris; Saif Hawari; Elise Noonan; Grace Styklunas; Sydney Crute; Sydney E Howard; Joanne Sheppard; Inga T Lennes; Francine Jacobson; Efren J Flores; Jennifer S Haas; Elyse R Park; Nancy A Rigotti Journal: Contemp Clin Trials Date: 2021-10-01 Impact factor: 2.226
Authors: Emily Kim; Randi M Williams; Ellie Eyestone; Marisa Cordon; Laney Smith; Kimberly Davis; George Luta; Eric D Anderson; Brady McKee; Juan Batlle; Michael Ramsaier; Judith Howell; Vicky Parikh; Maria Geronimo; Cassandra Stanton; Raymond Niaura; David Abrams; Kathryn L Taylor Journal: Contemp Clin Trials Date: 2021-05-06 Impact factor: 2.261
Authors: Hasmeena Kathuria; Frank C Detterbeck; Joelle T Fathi; Kathleen Fennig; Michael K Gould; Denise G Jolicoeur; Stephanie R Land; Greta M Massetti; Peter J Mazzone; Gerard A Silvestri; Christopher G Slatore; Robert A Smith; Anil Vachani; Steven B Zeliadt; Renda Soylemez Wiener Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 30.528
Authors: Christopher J Cadham; Pianpian Cao; Jinani Jayasekera; Kathryn L Taylor; David T Levy; Jihyoun Jeon; Elena B Elkin; Kristie L Foley; Anne Joseph; Chung Yin Kong; Jennifer A Minnix; Nancy A Rigotti; Benjamin A Toll; Steven B Zeliadt; Rafael Meza; Jeanne Mandelblatt Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 11.816
Authors: Amanda L Graham; Michael V Burke; Megan A Jacobs; Sarah Cha; Ivana T Croghan; Darrell R Schroeder; James P Moriarty; Bijan J Borah; Donna F Rasmussen; M Jody Brookover; Dale B Suesse; David E Midthun; J Taylor Hays Journal: Trials Date: 2017-11-28 Impact factor: 2.279
Authors: Anne M Joseph; Alexander J Rothman; Daniel Almirall; Abbie Begnaud; Caroline Chiles; Paul M Cinciripini; Steven S Fu; Amanda L Graham; Bruce R Lindgren; Anne C Melzer; Jamie S Ostroff; Elizabeth L Seaman; Kathryn L Taylor; Benjamin A Toll; Steven B Zeliadt; David M Vock Journal: Am J Respir Crit Care Med Date: 2018-01-15 Impact factor: 30.528